- Checkpoint Therapeutics (OTCQX:CKPT) initiated with Buy rating and $11 (139% upside) price target by H.C. Wainwright.
- Catalyst Biosciences (NASDAQ:CBIO) initiated with Buy rating and $19 (166% upside) price target by B. Riley FBR.
- DENTSPLY SIRONA (NASDAQ:XRAY) initiated with Buy rating and $81 (25% upside) price target by Deutsche Bank (DE:DBKGn).
- Teladoc (NYSE:TDOC) initiated with Buy rating and $39 (16% upside) price target by Deutsche Bank.
- Patterson Companies (NASDAQ:PDCO) initiated with Hold rating and $37 (5% upside) price target by Deutsche Bank.
- Repligen (NASDAQ:RGEN) initiated with Buy rating and $45 (30% upside) price target by Citigroup (NYSE:C).
- Athenahealth (NASDAQ:ATHN) initiated with Hold rating by Deutsche Bank.
- Align Technology (NASDAQ:ALGN) initiated with Hold rating by Deutsche Bank.
- Boston Scientific (NYSE:BSX) upgraded to Strong Buy by Needham.
- Celgene (NASDAQ:CELG) upgraded to Overweight by Atlantic Equities.
- Perrigo (NASDAQ:PRGO) upgraded to Buy by Argus Research.
- La Jolla Pharmaceutical (NASDAQ:LJPC) downgraded to Underweight by JPMorgan (NYSE:JPM).
- Source: Bloomberg
- Now read: scPharmaceuticals: A Recent IPO With A Novel Drug Delivery Platform
Original article